YAVNE, Israel, Nov. 6, 2015 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the Credit Suisse 24th Annual Healthcare Conference taking place from November 9-11, 2015 at the Phoenician Hotel in Scottsdale, Arizona. Gal Cohen, President and Chief Executive Officer, will deliver MediWound's corporate presentation on Wednesday, November 11th at 3:30 p.m. Mountain Time.
The Company's presentation will be webcast live on the internet and can be accessed by visiting the Investor Relations section of the Company's website at www.mediwound.com. A replay of the webcast will be archived on the MediWound website for 90 days following the presentation.
About MediWound Ltd.
MediWound is a fully integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, as well as chronic and other hard-to-heal wounds. MediWound's first innovative biopharmaceutical product, NexoBrid, received marketing authorization from the European Medicines Agency and from the Israeli and Argentinean Ministries of Health for removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns. NexoBrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and, without harming viable tissues. For more information, please visit www.mediwound.com.
Contacts:
Sharon Malka
Chief Financial & Operations Officer
MediWound
ir@mediwound.co.il
Anne Marie Fields
Senior Vice President
LHA
212-838-3777
afields@lhai.com